

Alzheimer's Disease (AD)

Why we do what we do – Alzheimer's Disease

Prevalence

- Globally, 440 lakh people are affected by dementia (majorly Alzheimer's)
- India has about 50 lakh dementia patients, (about 5% ; age > 65 years)
- 70-80 % of these dementia patients are Alzheimer's patients;
- Only 1-in-4 people with Alzheimer's disease are correctly diagnosed
- These numbers are expected to double by 2030

Mortality

- Alzheimer's Disease is the fourth leading cause of death in the Asia Pacific region

Impact on Caregivers (Quality of Life – QoL)

- The main caregivers are family members
- 60% of AD caregivers rate their emotional stress levels as high or very high
- 40% of AD caregivers suffer from depression (due to physical and emotional toll of caregiving)
- AD caregivers consider caregiving as additional healthcare costs of their own

Economic burden

- Total societal costs for Alzheimer's disease in India is about 14,700 crore
- Costs are expected to be three-fold by 2030

Risks of Alzheimer's Disease

Age

- Aging
- High risk after 65 years of age
- Rate of dementia doubles every decade after age 60

Gender

- Women are more likely than men to develop Alzheimer's

Family history and Genetics

- Family history account for less than 3% of Alzheimer's disease

Alzheimer's disease is taking away more than memory. If detected EARLY – it can be slowed and managed effectively

Our speciality

We use multimodal neuroimaging techniques to examine how normal aging and various forms of dementia affect the neural substrates of cognition. A primary scientific interest of the lab is to identify early neurochemical and functional biomarkers for neurodegenerative disorders, such as Alzheimer's disease (AD). We use magnetic resonance imaging (MRI), functional MRI (fMRI), and magnetic resonance spectroscopy (MRS) to investigate the respective structural, functional, and neurochemical brain alterations associated with healthy aging as well as neuro-degenerative disorders. The lab focuses on development and optimization of imaging protocols and tools to predict early AD.

Dr. Manjari Tripathi, MD,DM (Dept. of Neurology, AIIMS) is our close research collaborator for all clinical studies. NBRC conducts brain scan and awareness programs for early detection and effective management of AD. In the past 5 years, over ~400 people have been scanned for the disease out of which over 100 had early stages of AD. The youngest person to have symptoms of Alzheimer's at our screening was 39 year old.

MRI Screening @NBRC

- Free MRI brain scan reports
- Free transportation for needy person
- Clinical advice from Dr. Manjari, MD,DM at AIIMS

Symptoms of AD

- Memory loss that disrupts daily life
- Challenges in planning or solving problems
- Confusion with time or place
- Trouble understanding visual images and spatial relationships
- New problems in words in speaking or writing
- Misplacing things and losing ability to retrace steps
- Decreased or poor judgement
- Withdrawal from work or social activities
- Changes in mood and personality

Neuropsychological Support :

- *Mrs Shallu Joon, M.Phil* (Neuropsychologist)

At the Lab, our neuropsychologists assesses and evaluates participants on a wide range of cognitions like memory, language, thoughts, perception, attention etc.

Appointments: Please email pravat.clinical2@gmail.com or call on 8377002213

webpage:
<http://www.nbrc.ac.in>

Contact

Dr. Pravat K Mandal
Dr. Deepika Shukla

Email:

pravat.mandal@gmail.com
deepika.shukla0914@gmail.com

Phone: +91-8377002213

Address: NeuroImaging and
NeuroSpectroscopy Lab
National Brain Research
Centre (NBRC)
NH-8, Manesar, Gurgaon
Haryana-122 051
India

Working hours: 9 am – 5.30 pm
(Monday-Friday)